Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model

Trial Profile

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs EDP 938 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Enanta Pharmaceuticals
  • Most Recent Events

    • 15 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 28 Sep 2018 Status changed from planning to not yet recruiting.
    • 12 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top